Sign in

    Phebe

    Research Analyst at Jefferies

    No comprehensive professional profile for a Phebe, Phoebe, or similar analyst at Jefferies was found through available search results. No LinkedIn profile, job titles, coverage sectors, or performance credentials could be identified for a Jefferies analyst by this name. Without verifiable data, there is no record of a Phebe serving as an equity research analyst or holding another analyst role at Jefferies with coverage of public companies, performance track record, or recognized financial credentials.

    Phebe's questions to SLRN leadership

    Phebe's questions to SLRN leadership • Q2 2024

    Question

    Asked about the target patient population for the uveitis trial (refractory vs. not), its potential for an orphan indication designation, and the feasibility of orphan pricing given existing competition from HUMIRA.

    Answer

    The uveitis trial includes patients with active disease, some of whom have prior biologic exposure. The company sees a high unmet need and an opportunity to expand the market but stated it is too early to comment on specific pricing strategies.

    Ask Fintool Equity Research AI